Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

In this study, baricitinib was effective in improving hair regrowth in patients with severe alopecia areata over one year, especially when treatment began within four years of symptom onset.

Baricitinib helps with early hair regrowth in people with alopecia areata.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

This paper discusses the importance of early diagnosis and treatment of polycystic ovarian syndrome to potentially reduce long-term complications like diabetes, hypertension, and heart disease, but reports no new clinical outcomes.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

This study analyzed CADR reports in Singapore, finding nonsteroidal anti-inflammatory drugs, antibiotics, and iohexol frequently associated with serious skin reactions like rash and angioedema, with trends varying by demographics.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

This study found a significant psychosocial and occupational burden on caregivers of adolescents with alopecia areata in Australia, impacting their mental and emotional well-being and emphasizing the need to recognize the broader effects of the condition beyond the patients themselves.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This case report describes a 62-year-old male with multiple warty dyskeratomas found on the scalp, chest, abdomen, and lower back, a rare presentation confirmed by histological findings consistent with warty dyskeratoma, as noted by the researchers.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This study found that Japanese patients with alopecia areata had higher body mass index and retinol intake, with retinol intake being a predictor of hair loss severity.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.